VIVO Cannabis Announces Publication of Medical Cannabis Clinical Research Study in Psychiatric Research: Anxiety & Depression Outcomes in Medical Cannabis Patients
Toronto, Ontario--(Newsfile Corp. - June 3, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms"), ABcann Medicinals Inc., today announced results from its first study investigating how medical cannabis impacts anxiety and depression outcomes. The publication, entitled "Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study" was published in the peer-reviewed journal Psychiatry Research and was completed by VIVO's Harvest Medicine Inc ("HMED") subsidiary. To the Company's knowledge, it is the largest study to date of its kind, examining the impact of medical cannabis using longitudinal data and completed validated questionnaires for anxiety (GAD-7) and depression (PHQ-9) in 7,362 Canadian patients. Analyses were conducted for three different timepoints: 3-6 months, 12-18 months, and 24 months or greater.
The study was led by HMED's team of prescribing clinicians and physician support staff. Patients using medical cannabis for anxiety and/or depression saw statistically significant improved outcomes between baseline and follow-up scores. This study provides some evidence to support the effectiveness of medical cannabis as a treatment for anxiety and depression.
"Since 2017, Harvest Medicine has been an industry-leading, high volume cannabis clinic network, and our team has worked hard to share these clinical insights in an effort to contribute to the medical cannabis literature and to reduce stigma amongst health care professionals," said Carole Chan, RPh, President of Harvest Medicine. "We are committed to further research and advancing patient outcomes with an evidence-informed approach to patient care."
About VIVO Cannabis
VIVO Cannabis® is recognized for trusted, premium cannabis products and services. Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical®, Fireside™, and Lumina™. Harvest Medicine™, VIVO's patient-centric, scalable network of medical cannabis clinics, has serviced over 200,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com
For further information:
VIVO Investor Relations
Michael Bumby, Chief Financial Officer
Disclaimer for Forward-Looking Information
Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company's most recent management's discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/126374